早期肿瘤退缩与白蛋白紫杉醇联合吉西他滨一线治疗晚期胰腺癌效果及预后的关系OACSTPCD

Objective To explore the relationship of efficacy and prognosis between early tumor shrinkage(ETS)and albumin paclitaxel combined with gemcitabine(AG regimen)in the first-line treatment of advanced pancreatic cancer.Methods A retrospective analysis was conducted on 38 advanced pancreatic cancer patients in Shaoxing Central Hospital from Jan.2018 to Jan.2023.The optimum critical value of ETS was analyzed by receiver operating characteristic(ROC)curve.Survival analysis was conducted by Kaplan-Meier method and Log-rank test,and the relationship between ETS and the prognosis of advanced pancreatic cancer was analyzed by Cox regression.Results For the 38 advanced pacreatic patients,the median progression-free survival(PFS)was 6.20(95%CI 5.90-6.50)months,the median overall survival(OS)was 12.00(95%CI 9.74-14.27)months,the disease control rate(DCR)was 82.6%,and the best critical value of ETS was 9.25%.The patients with ETS≥9.25%(n=17)had longer PFS(8.00 months vs 4.80 months,P<0.05)and OS(16.50 months vs 10.20 months,P<0.05)than those with ETS<9.25%(n=21).Cox multivariate regression analysis showed that ETS was an independent factor affecting the survival and prognosis of advanced pancreatic cancer(PFS:HR=0.341,95%CI 0.135-0.680,P<0.05;OS:HR=0.225,95%CI 0.084-0.603,P<0.05).Conclusion The AG regimen is effective in the first-line treatment of advanced pancreatic cancer.ETS can effectively predict the efficacy and prognosis of advanced pancreatic cancer with AG regimen.